Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Fingolimod, a sphingosine-1 phosphate receptor modulator, increases BDNF levels and improves symptoms of a mouse model of Rett syndrome.
CHMP determines dimethyl fumarate in TECFIDERA® to be a new active substance in the European Union
A study to evaluate the effect of ultrasound treatment on nodules in multiple sclerosis patients.
Genzyme Announces Successful Phase III Results for Alemtuzumab (LEMTRADA TM*) in Multiple Sclerosis
Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticity.
Development of a recombinant immunotoxin for the immunotherapy of autoreactive lymphocytes expressing MOG-specific BCRs.
Generation of demyelination models by targeted ablation of oligodendrocytes in the zebrafish CNS.
Visualizing Non-Gaussian Diffusion: Clinical Application of q-Space Imaging and Diffusional Kurtosis Imaging of the Brain and Spine.
Zebrafish: A new vertebrate model for visualizing myelination in vivo.
Interferon beta-1a therapy enhances CD4+ regulatory T-cell function: an ex vivo and in vitro longitudinal study in relapsing-remitting multiple sclerosis.
Peripheral Bilateral Telangiectasiae in Multiple Sclerosis Patients Treated with Interferon B1a.
Diagnosis and treatment of hyponatraemia.
Relationship between neuromuscular and perceived fatigue and locomotor performance in patients with multiple sclerosis.
Laquinimod in Relapsing-Remitting Multiple Sclerosis
Morphogenesis of the demyelinating lesions in Baló's concentric sclerosis.
More Than 15 Years of Experience with Intradetrusor OnabotulinumtoxinA Injections for Treating Refractory Neurogenic Detrusor Overactivity: Lessons to Be Learned.
Magnetic resonance imaging outcomes from a phase III trial of teriflunomide.
Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial.
Optical coherence tomography and neurodegeneration: are eyes the windows to the brain?
Treatment with Trichuris suis soluble products during monocyte-to-macrophage differentiation reduces inflammatory responses through epigenetic remodeling.
Evaluation of quality of life and fatigue in radiologically isolated syndrome.
Beta-Interferon, Glatiramer Acetate Cost-Effective in MS
A case of posterior reversible encephalopathy syndrome associated with gilenya(®) (fingolimod) treatment for multiple sclerosis.
Dimethyl fumarate attenuates cerebral edema formation by protecting the blood-brain barrier integrity.
The Effects of IFN-β 1a on the Expression of Inflammasomes and Apoptosis-Associated Speck-Like Proteins in Multiple Sclerosis Patients.
Pages
« first
‹ previous
…
80
81
82
83
84
85
86
87
88
…
next ›
last »